Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma.

[Sho Yoshimoto,Daiki Kato,Satoshi Kamoto,Kie Yamamoto,Masaya Tsuboi,Masahiro Shinada,Namiko Ikeda,Yuiko Tanaka,Ryohei Yoshitake,Shotaro Eto,Kohei Saeki,James Chambers,Ryohei Kinoshita,Kazuyuki Uchida,Ryohei Nishimura,Takayuki Nakagawa]

The human epidermal growth factor receptor 2 (HER2) is expressed in various human cancers including thyroid cancers (TC) and is used as a diagnostic marker and therapeutic target. Canine TC (cTC), the most common endocrine malignancy in dogs, shows a high metastasis rate, and HER2-targeted therapy could be a candidate for treatment. Here, we immunohistochemically evaluated HER2 expression in 21 paraffin-embedded cTC tissues and scored the degree of expression based on intensity and positivity (score: 0-3+). Four samples (19%) scored 3+; 6 (29%), 2+; 7 (33%), 1+; and 4 (19%), 0. Therefore, 48% of the cTC tissues were HER2 positive (scored ?2+). These data may lead to further evaluation of the role of HER2 in cTC as a mechanism of malignancy and a therapeutic target.

Heliyon

5

7

e02004